DMRA

Damora Therapeutics
$29.44
+$0.62 (+2.15%)Jul 27, 2026
4.3NeutralMoatMint rating

MoatMint rates Damora Therapeutics (DMRA) 4.3 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.5 out of 10.

Key metrics

The numbers that frame DMRA today
Market cap
$1.81B
P/E (TTM)
-7.7
EV / FCF
-51.4
ROIC
2,547.1%
Div yield
0%
Debt / equity
0.0
52wk Low
$2.45
52wk High
$38.33

DMRA stock rating

How DMRA scores on quality, value, growth, momentum and financial health
4.3out of 10
Neutral overallHealthy business, expensive priceTop 57% of ~5,000 US stocks
QualityPoor0.5/10
GrowthGreat10/10
MomentumGreat9.7/10
ValueFair2.7/10
Financial HealthFair2.4/10

Growth

Revenue and earnings trend for DMRA
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about DMRA
Is Damora Therapeutics a good buy?
Hold. Damora Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Damora Therapeutics is selling at a high price.
What is the market capitalization of DMRA?
Damora Therapeutics's market capitalization is $1.81B.
What is the P/E ratio for DMRA stock?
Damora Therapeutics's current P/E ratio is -7.7.
What is the 52-week high for DMRA stock?
The 52-week high for Damora Therapeutics is $38.33. The current close of $29.44 is 23.2% below that high.
What is the 52-week low for DMRA stock?
The 52-week low for Damora Therapeutics is $2.45. The current close of $29.44 is 1,101.6% above that low.
Does DMRA stock pay dividends?
Damora Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for DMRA?
Damora Therapeutics's Debt / Equity ratio is 0.